Persistent abnormalities in red cell parameters following treatment of XXXX .

@entity1 @entity706 @entity2590 @entity3052 @entity1893 @entity978 @entity30030
@entity1 who have recovered from @entity706 are at an increased risk of secondary @entity3052 ( @entity3052 ), and overt @entity3052 is frequently preceded by a @entity2590 . Although the statistical risk is significant, only a minority of the @entity1 will be so affected. We have reviewed peripheral blood counts of @entity1 with @entity978 ( @entity978 ) and @entity1893 ( @entity1893 ) treated in the Departments of Hematology at the Edith Wolfson and Chaim Sheba Medical Centers, Israel. Included were only those who went into a complete remission and remained @entity706 free for extended periods. There were 85 @entity1 with @entity978 and 36 with @entity1893 . In both groups peripheral blood counts at diagnosis were within the normal range. A prolonged follow-up (> 4 y), during which no further treatment was given, revealed a sustained increment over time of MCV (delta MCV) both in @entity978 and @entity1893 . A persistent @entity30030 in @entity978 @entity1 was also evident. delta MCV was larger in @entity978 . The difference at the end of the follow-up period was as follows: 10.1 fl + 11.8 in @entity978 vs 5.0 fl + 6.2 in @entity1893 , (P < 0.001). In addition, a significant loss of the normal correlation between the MCV and levels of hemoglobin was seen at the last follow-up. The change in MCV was present in all treatment groups, its magnitude increasing from radiotherapy to chemotherapy to combined radio chemotherapy. This trend is in analogy to the risk of secondary @entity3052 which is lower in @entity1893 vs @entity978 . Furthermore, it is lowest post radiotherapy and highest when both treatment modalities are used.(ABSTRACT TRUNCATED AT 250 WORDS)
